Viking Therapeutics (VKTX) Total Non-Current Liabilities (2014 - 2025)
Viking Therapeutics (VKTX) reported Total Non-Current Liabilities of $318000.0 for Q3 2025, down 57.88% on a YoY basis from $755000.0 in Q3 2024, and down 22.44% sequentially from $410000.0 in Q2 2025.
Viking Therapeutics (VKTX) Total Non-Current Liabilities (2014 - 2025) Analysis & Trends
Viking Therapeutics (VKTX) has 11 years of Total Non-Current Liabilities data on file, last reported at $318000.0 in Q3 2025.
- For the quarter ending Q3 2025, Total Non-Current Liabilities fell 57.88% year-over-year to $318000.0; the trailing twelve-month figure through Sep 2025 stood at $318000.0 (down 57.88% YoY), and the FY2024 full-year result was $630000.0, down 32.69% from the prior year.
- Total Non-Current Liabilities slipped to $318000.0 in Q3 2025, from $410000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.5 million in Q1 2022 to a low of $318000.0 in Q3 2025.
- A 4-year average of $931266.7 and a median of $936000.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities slipped 20.74% in 2023 and sank 57.88% in 2025, its largest moves.
- Tracing VKTX's Total Non-Current Liabilities over 4 years: stood at $1.3 million in 2022, then dropped by 25.71% to $936000.0 in 2023, then sank by 32.69% to $630000.0 in 2024, then slumped by 49.52% to $318000.0 in 2025.
- Business Quant data shows VKTX's Total Non-Current Liabilities at $318000.0 in Q3 2025, $410000.0 in Q2 2025, and $502000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 318,000.00 |
| Jun 30, 2025 | 410,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Dec 31, 2024 | 630,000.00 |
| Sep 30, 2024 | 755,000.00 |
| Jun 30, 2024 | 766,000.00 |
| Mar 31, 2024 | 852,000.00 |
| Dec 31, 2023 | 936,000.00 |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 1.26 Mn |
| Sep 30, 2022 | 1.34 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 1.49 Mn |
| Dec 31, 2020 | 29,000.00 |
| Sep 30, 2020 | 115,000.00 |
| Jun 30, 2020 | 198,000.00 |
| Mar 31, 2020 | 279,000.00 |
| Dec 31, 2019 | 360,000.00 |